Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, September 22, 2015

Andrographolide stimulates neurogenesis in the adult hippocampus

This may be in mice but hell it should be added to the stroke strategy and research sponsored to find out if this works in humans. Damn, so much research to do and no one to direct it.
http://scholar.google.com/scholar_url?url=http://downloads.hindawi.com/journals/np/aip/935403.pdf&hl=en&sa=X&scisig=AAGBfm3ZwPw89YwMS9BnvOh-BMJyfx92HA&nossl=1&oi=scholaralrt


Lorena Varela-Nallar, PhD 1*, Sebastian B. Arredondo, MSc1, Cheril Tapia-Rojas, MSc 2,
Juan Hancke, DVM 3, and Nibaldo C. Inestrosa, PhD 2,4,5,*.
1Centro de Investigaciones Biomédicas (CIB), Facultad de Ciencias Biológicas y Facultad
de Medicina, Universidad Andrés Bello, Santiago, Chile
2Centro de Envejecimiento y Regeneración (CARE), Departamento de Biología Celular y
Molecular, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile,
Santiago, Chile.
4Instituto de Farmacología y Morfofisiología, Universidad Austral de Chile, Valdivia,
Chile.
5Center for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of
New South Wales, Sydney, Australia
6Centro de Excelencia en Biomedicina de Magallanes (CEBIMA), Universidad de
Magallanes, Punta Arenas, Chile.
Running title: Andrographolide stimulates adult neurogenesis
*Correspondence: Dr. Lorena Varela-Nallar, Center for Biomedical Research, Universidad
Andrés Bello, República 239, 8370146, Santiago, Chile. E-mail: lorena.varela@unab.cl;
Dr. Nibaldo C. Inestrosa, CARE Biomedical Center, Pontificia Universidad Católica de
Chile, Alameda 340, P. O. Box 114-D, Santiago, Chile. E-mail: ninestrosa@bio.puc.cl.
2
Abstract
Andrographolide (ANDRO) is a labdane diterpenoid component of Andrographis
paniculata widely used for its anti-inflammatory properties. We have recently determined
that ANDRO is a competitive inhibitor of glycogen synthase kinase-3â (GSK-3â), a key
enzyme of the Wnt/â-catenin signaling cascade. Since this signaling pathway regulates
neurogenesis in the adult hippocampal dentate gyrus, we evaluated whether ANDRO is
able to stimulate this process. Treatment with ANDRO increased neural progenitor cell
proliferation and the number of immature neurons in the hippocampus of 2- and 10-monthold
mice compared to age-matched control mice. Moreover, ANDRO stimulated a net
increase in neurogenesis increasing the number of newborn dentate granule neurons. Also,
the effect of ANDRO was evaluated in the double transgenic APPswe/PS1ÄE9 mouse
model of Alzheimer’s disease. In these mice, ANDRO increased cell proliferation and the
density of immature neurons in the dentate gyrus. Concomitantly with the increase in
neurogenesis, ANDRO induced the activation of the Wnt signaling pathway in the
hippocampus of wild-type and APPswe/PS1ÄE9 mice determined by increased levels of â-
catenin, the inactive form of GSK-3â, and NeuroD1, a Wnt target gene involved in
neurogenesis. Our findings indicate that ANDRO stimulates neurogenesis in the adult
hippocampus suggesting that this drug could be used as a therapy in diseases in which
neurogenesis is affected.
 


No comments:

Post a Comment